These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
117 related articles for article (PubMed ID: 38517161)
1. Resolution of severe neurobehavioral difficulties in an individual with Primrose syndrome with sertraline. Moon YM; Park SE; Smith-Hicks C; Hauptman A Am J Med Genet A; 2024 Aug; 194(8):e63610. PubMed ID: 38517161 [TBL] [Abstract][Full Text] [Related]
2. Refining the Primrose syndrome phenotype: A study of five patients with ZBTB20 de novo variants and a review of the literature. Cleaver R; Berg J; Craft E; Foster A; Gibbons RJ; Hobson E; Lachlan K; Naik S; Sampson JR; Sharif S; Smithson S; ; Parker MJ; Tatton-Brown K Am J Med Genet A; 2019 Mar; 179(3):344-349. PubMed ID: 30637921 [TBL] [Abstract][Full Text] [Related]
3. Novel de novo mutations in ZBTB20 in Primrose syndrome with congenital hypothyroidism. Mattioli F; Piton A; Gérard B; Superti-Furga A; Mandel JL; Unger S Am J Med Genet A; 2016 Jun; 170(6):1626-9. PubMed ID: 27061120 [TBL] [Abstract][Full Text] [Related]
4. Expansion of the Primrose syndrome phenotype through the comparative analysis of two new case reports with ZBTB20 variants. Ferreira LD; Borges-Medeiros RL; Thies J; Schnur RE; Lam C; de Oliveira JRM Am J Med Genet A; 2019 Nov; 179(11):2228-2232. PubMed ID: 31321892 [TBL] [Abstract][Full Text] [Related]
5. Novel de novo mutation in ZBTB20 in a Chinese Primrose syndrome family and a review of the literature. Li J; Zhang C; Tian X; Zhou B; Chen X; Wang Y; Hao S; Hui L; Meng Z Mol Genet Genomic Med; 2024 Jan; 12(1):e2304. PubMed ID: 38087819 [TBL] [Abstract][Full Text] [Related]
6. Primrose syndrome associated with unclassified immunodeficiency and a novel ZBTB20 mutation. Yamamoto-Shimojima K; Imaizumi T; Akagawa H; Kanno H; Yamamoto T Am J Med Genet A; 2020 Mar; 182(3):521-526. PubMed ID: 31821719 [TBL] [Abstract][Full Text] [Related]
7. Novel de novo mutation in ZBTB20 in primrose syndrome in boy with short stature. Grímsdóttir S; Hove HB; Kreiborg S; Ek J; Johansen A; Darvann TA; Hermann NV Clin Dysmorphol; 2019 Jan; 28(1):41-45. PubMed ID: 30256248 [No Abstract] [Full Text] [Related]
8. Novel de novo ZBTB20 mutations in three cases with Primrose syndrome and constant corpus callosum anomalies. Alby C; Boutaud L; Bessières B; Serre V; Rio M; Cormier-Daire V; de Oliveira J; Ichkou A; Mouthon L; Gordon CT; Bonnière M; Mechler C; Nitschke P; Bole C; Lyonnet S; Bahi-Buisson N; Boddaert N; Colleaux L; Roth P; Ville Y; Vekemans M; Encha-Razavi F; Attié-Bitach T; Thomas S Am J Med Genet A; 2018 May; 176(5):1091-1098. PubMed ID: 29681083 [TBL] [Abstract][Full Text] [Related]
15. Pilot of a randomised controlled trial of the selective serotonin reuptake inhibitor sertraline versus cognitive behavioural therapy for anxiety symptoms in people with generalised anxiety disorder who have failed to respond to low-intensity psychological treatments as defined by the National Institute for Health and Care Excellence guidelines. Buszewicz M; Cape J; Serfaty M; Shafran R; Kabir T; Tyrer P; Clarke CS; Nazareth I Health Technol Assess; 2017 Aug; 21(45):1-138. PubMed ID: 28853392 [TBL] [Abstract][Full Text] [Related]
16. ZBTB20 is crucial for the specification of a subset of callosal projection neurons and astrocytes in the mammalian neocortex. Medeiros de Araújo JA; Barão S; Mateos-White I; Espinosa A; Costa MR; Gil-Sanz C; Müller U Development; 2021 Aug; 148(16):. PubMed ID: 34351428 [TBL] [Abstract][Full Text] [Related]
17. Sertraline response in adults with mental retardation and autistic disorder. Hellings JA; Kelley LA; Gabrielli WF; Kilgore E; Shah P J Clin Psychiatry; 1996 Aug; 57(8):333-6. PubMed ID: 8778118 [TBL] [Abstract][Full Text] [Related]
19. New case of Primrose syndrome with mild intellectual disability. Posmyk R; Leśniewicz R; Chorąży M; Wołczyński S Am J Med Genet A; 2011 Nov; 155A(11):2838-40. PubMed ID: 21910247 [TBL] [Abstract][Full Text] [Related]
20. A randomised controlled trial assessing the severity and duration of depressive symptoms associated with a clinically significant response to sertraline versus placebo, in people presenting to primary care with depression (PANDA trial): study protocol for a randomised controlled trial. Salaminios G; Duffy L; Ades A; Araya R; Button KS; Churchill R; Croudace T; Derrick C; Dixon P; Dowrick C; Gilbody S; Hollingworth W; Jones V; Kendrick T; Kessler D; Kounali D; Lanham P; Malpass A; Peters TJ; Riozzie D; Robinson J; Sharp D; Thomas L; Welton NJ; Wiles N; Lewis G Trials; 2017 Oct; 18(1):496. PubMed ID: 29065916 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]